SCHEMBL1706746

SCHEMBL1706746

CC(=O)c1cccc(Cc2nc(NC(=O)OC(C)(C)C)co2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.38
SLC7A5 Q01650 1/20 0.38
FPR2 P25090 1/20 0.38
CYP17A1 P05093 2/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
IL4I1 Q96RQ9 1/20 0.36
BRD4 O60885 1/20 0.36
SCN9A Q15858 2/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31478407 0.79 SCN9A (0.36) LMNAFPR2CYP17A1MEN1POLB
SCHEMBL27899559 0.77 LMNA (0.38) LMNAMAPTMAPK1MEN1POLB
SCHEMBL1706233 0.75 LOXL2 (0.44) LMNAMAPTMAPK1SLC7A5MEN1
SCHEMBL2683295 0.74 MAOB (0.47) LMNAMAPK1MEN1KMT2ANPC1
SCHEMBL2683292 0.74 MAOB (0.47) LMNAMAPK1MEN1KMT2ANPC1
SCHEMBL27899558 0.74 IL4I1 (0.36) LMNAMAPTMAPK1SLC7A5MEN1
SCHEMBL1707161 0.73 LMNA (0.43) LMNAMAPTMAPK1MEN1POLB
SCHEMBL1706806 0.72 IL4I1 (0.42) LMNAMAPTMAPK1MEN1POLB
SCHEMBL28802129 0.72 LMNA (0.43) LMNAMAPTMAPK1SLC7A5MEN1
SCHEMBL14098889 0.72 PTGER1 (0.62) CYP2C9PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 LMNA 3835/4885MAPT 3232/4885MAPK1 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.